Literature DB >> 18056006

Imatinib mesylate in combination with chemotherapy in four children with de novo and advanced stage Philadelphia chromosome-positive acute lymphoblastic leukemia.

José Luis Fuster1, Mar Bermúdez, Ana Galera, María Esther Llinares, Doris Calle, Francisco Jose Ortuño.   

Abstract

The role of imatinib in childhood Philadelphia chromosome-positive (Ph(+)) acute lymphoblastic leukemia (ALL) has not been established. We treated four children with imatinib in combination with conventional chemotherapy (CT) before stem cell transplantation (SCT). Response evaluation consisted of fluorocytometric analysis of minimal residual disease (MRD) and standard qualitative RT-PCR follow-up.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18056006     DOI: 10.3324/haematol.11525

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  1 in total

1.  Impact of age, leukocyte count and day 21-bone marrow response to chemotherapy on the long-term outcome of children with philadelphia chromosome-positive acute lymphoblastic leukemia in the pre-imatinib era: results of the FRALLE 93 study.

Authors:  Virginie Gandemer; Marie-Francoise Auclerc; Yves Perel; Jean-Pierre Vannier; Edouard Le Gall; Francois Demeocq; Claudine Schmitt; Christophe Piguet; Jean-Louis Stephan; Odile Lejars; Marianne Debre; Philippe Jonveaux; Jean-Michel Cayuela; Sylvie Chevret; Guy Leverger; Andre Baruchel
Journal:  BMC Cancer       Date:  2009-01-13       Impact factor: 4.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.